Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis

Last updated: March 29, 2016
Sponsor: ALK-Abelló A/S
Overall Status: Completed

Phase

3

Condition

Common Cold

Allergies & Asthma

Allergy (Pediatric)

Treatment

N/A

Clinical Study ID

NCT01603056
PS-M-01
  • Ages 5-55
  • All Genders

Study Summary

Primary aim is to evaluate the efficacy of specific immunotherapy with Pangramin SLIT HDM-mix compared to placebo in the treatment of House Dust Mite (HDM) induced rhinitis with or without asthma.

Sublingual immunotherapy has been used during several years and has been shown to provide benefits compare to traditional subcutaneous treatment. This study will investigate if improvements in rhinitis symptoms and less use of symptomatic medication can be obtained as a consequence of being treated under specific immunotherapy.

This study aim also to contribute to the documentation of tolerability and safety profile of Pangramin HDM Mix.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female ≥ 5 to ≤ 55 years of age.

  • A history HDM induced allergic rhinitis.

  • Use of medication for the control of rhinoconjunctivitis symptoms.

  • Positive Skin Prick Test (SPT).

  • Positive specific IgE.

Exclusion

Exclusion Criteria:

  • PEF ≤ 70% of predicted value.

  • History of significant symptomatic seasonal or perennial allergic rhinitis and/orasthma caused by an allergen to which the patient is regularly exposed, and sensitized (e.g. pollens, cat, dog, cockroach…except house dust mites).

  • Severe asthma.

  • Current symptoms of upper respiratory tract infection or other relevant infectiousprocess.

  • Current food allergies with oral allergy syndrome.

  • A clinical history of chronic sinusitis.

  • Current severe atopic dermatitis.

  • Concomitant or previous treatment by immunotherapy.

Study Design

Total Participants: 617
Study Start date:
October 01, 2009
Estimated Completion Date:
February 29, 2012

Study Description

Extensive clinical experience has been gained due to the widespread use of Pangramin® SLIT and other SLIT products as named patient products, both with respect to the types and the frequencies of the adverse events(AEs) observed. No safety concerns have been found.

The optimal therapeutic dose range regarding SLIT is not fully elucidated. The fate of the allergen after sublingual administration is not known in detail, i.e. to what extent is the allergen absorbed over the mucosa or swallowed and how this is related to volume, excipients etc. The relationship between dose and effect is thus not fully elucidated. The general recommendation is to use a dose inducing a clinical relevant effect in most patients without causing unacceptable adverse events. As Pangramin SLIT HDM-mix has a safety profile that allows a single daily intake by the patient at home, the dosage at this trial will be the same as marketed product.

Connect with a study center

  • No.2, Chongwenmennei Street, Dongcheng District

    Beijing, Beijing 100730
    China

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.